Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY 4.0BMJ Open

Exclude or expose in irritable bowel syndrome study: what works for whom and how? Protocol for a randomised controlled trial of internet-delivered FODMAP diet versus exposure-based cognitive behavioural therapy

8 affiliations
  1. 1Human Nutrition Group, Faculty of Science, The University of Melbourne, Melbourne, Victoria, Australia
  2. 2Department of Clinical Neuroscience, Division of Psychology, Karolinska Institute, Stockholm, Sweden
  3. 3Harvard Medical School, Boston, Massachusetts, USA
  4. 4Center for Neurointestinal Health, Massachusetts General Hospital, Boston, Massachusetts, USA
  5. 5Department of Gastroenterology, Alfred Health, Monash University, Melbourne, Victoria, Australia
  6. 6Department of Gastroenterology, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia
  7. 7Department of Medicine, The University of Melbourne, St Vincent’s Hospital, Melbourne, Victoria, Australia
  8. 8Laboratory for Brain-Gut Axis Studies (LaBGAS),Translational Research Centre for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases & Metabolism (CHROMETA), KU Leuven, Leuven, Belgium

Abstract

Introduction: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterised by abdominal pain and altered bowel habits and is associated with reduced quality of life. Although several treatments are effective at the group level, treatment responses vary substantially between individuals, highlighting the need for personalised approaches. This trial investigates moderators and mediators of treatment response to two established IBS interventions to determine for whom treatments are most effective and how they exert their effects.

Methods and analysis: This parallel-group randomised controlled trial will enrol 235 adults with IBS from community, primary and tertiary care across Australia and the US. Participants will be randomised to a 12 week online fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet intervention targeting reduction of fermentable carbohydrate intake or an exposure-based cognitive behavioural therapy (E-CBT) programme targeting symptom-related avoidance behaviours, each with therapist support (dietitian or psychologist, respectively). The primary objective is to assess moderators and mediators of treatment response on gastrointestinal symptom severity, measured using the Gastrointestinal Symptom Rating Scale (GSRS-IBS), assessed weekly from baseline to week 12. Pre-specified moderators and mediators include gastrointestinal-specific anxiety and avoidance behaviour and total FODMAP intake; treatment preference will also be examined as a moderator. Treatment expectancy and credibility and therapeutic alliance will be assessed as covariates accounting for non-specific treatment effects. Secondary outcomes, assessed at baseline, post-treatment (12 weeks) and 3- and 6-month post-intervention follow-up, include IBS-specific symptom severity (measured using the IBS-Symptom Severity Scale, IBS-SSS), IBS-related quality of life, eating-related symptoms, psychological symptoms, extraintestinal symptom distress, stool frequency and consistency and gut microbiome composition and function. We will also assess gastrointestinal symptom severity by the GSRS-IBS at 3- and 6-month follow-up to assess maintenance. Linear mixed-effects models will assess treatment effects and moderation. Latent growth curve modelling and time-lagged mixed-effects models will examine mediation.

Ethics and dissemination: Ethical approval was obtained from the University of Melbourne Human Research Ethics Committee (Project ID: 31186). This manuscript is based on protocol V.4.0 (06–04-26). Recruitment is ongoing. Results will be disseminated via peer-reviewed publications and presentations at scientific meetings.

Trial registration number: NCT06940596.

Related

  1. A randomised controlled feasibility trial of guided parent-delivered cognitive behaviour therapy for children’s perfectionism
    Tracey D. Wade, Sarah J. Egan, Maya Jabs +2
    European Child & Adolescent PsychiatryPeer-reviewedCC BY 4.0Full text1 citedPsychiatry & mental healthPMC
  2. ACTIVATE: A protocol for a randomised controlled evaluation of Thumos: A cognitive-behavioural intervention for medical students
    Lucy Pointon, William Lea, Christopher D. J. Taylor +19
    PLOS OnePeer-reviewedCC BY 4.0Full textPsychiatry & mental healthPLOS
  3. Cognitive behavioural therapy compared to compensatory strategy training for persisting memory symptoms after concussion in adults: protocol for a randomised controlled trial
    Noah D. Silverberg, Matthew J. Burke, Chantel T Debert +12
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textNeurologyCrossrefDOAJPMC
  4. Comparative effectiveness of exercise and self-management interventions delivered through different modes of digital support on pain and patient-reported physical function in people with knee osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials
    Hao Luo, Guoqing Zhang, Lingyun Long +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Lifestyle therapy versus cognitive behavioural therapy for adults with mood disorders: a randomised non-inferiority trial
    A. O'Neil, K. Richardson, J. A. Davis +28
    medRxivPreprintAll rights reservedFull textPsychiatry & mental healthmedRxiv
BibTeX
@article{anderson2026exclude,
  title = {{Exclude or expose in irritable bowel syndrome study: what works for whom and how? Protocol for a randomised controlled trial of internet-delivered FODMAP diet versus exposure-based cognitive behavioural therapy}},
  author = {Jacqueline L Anderson and Brjánn Ljótsson and Helen Burton-Murray and Madeline L West and Chu K Yao and Chamara Basnayake and Lukas Van Oudenhove and Jessica R Biesiekierski},
  journal = {BMJ Open},
  year = {2026},
  month = nov,
  doi = {10.1136/bmjopen-2026-126664},
  url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-126664},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Exclude or expose in irritable bowel syndrome study: what works for whom and how? Protocol for a randomised controlled trial of internet-delivered FODMAP diet versus exposure-based cognitive behavioural therapy
AU  - Jacqueline L Anderson
AU  - Brjánn Ljótsson
AU  - Helen Burton-Murray
AU  - Madeline L West
AU  - Chu K Yao
AU  - Chamara Basnayake
AU  - Lukas Van Oudenhove
AU  - Jessica R Biesiekierski
PY  - 2026
DA  - 2026/11/11
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-126664
UR  - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-126664
AB  - Introduction: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterised by abdominal pain and altered bowel habits and is associated with reduced quality of life. Although several treatments are effective at the group level, treatment responses vary substantially between individuals, highlighting the need for personalised approaches. This trial investigates moderators and mediators of treatment response to two established IBS interventions to determine for whom treatments are most effective and how they exert their effects.  Methods and analysis: This parallel-group randomised controlled trial will enrol 235 adults with IBS from community, primary and tertiary care across Australia and the US. Participants will be randomised to a 12 week online fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet intervention targeting reduction of fermentable carbohydrate intake or an exposure-based cognitive behavioural therapy (E-CBT) programme targeting symptom-related avoidance behaviours, each with therapist support (dietitian or psychologist, respectively). The primary objective is to assess moderators and mediators of treatment response on gastrointestinal symptom severity, measured using the Gastrointestinal Symptom Rating Scale (GSRS-IBS), assessed weekly from baseline to week 12. Pre-specified moderators and mediators include gastrointestinal-specific anxiety and avoidance behaviour and total FODMAP intake; treatment preference will also be examined as a moderator. Treatment expectancy and credibility and therapeutic alliance will be assessed as covariates accounting for non-specific treatment effects. Secondary outcomes, assessed at baseline, post-treatment (12 weeks) and 3- and 6-month post-intervention follow-up, include IBS-specific symptom severity (measured using the IBS-Symptom Severity Scale, IBS-SSS), IBS-related quality of life, eating-related symptoms, psychological symptoms, extraintestinal symptom distress, stool frequency and consistency and gut microbiome composition and function. We will also assess gastrointestinal symptom severity by the GSRS-IBS at 3- and 6-month follow-up to assess maintenance. Linear mixed-effects models will assess treatment effects and moderation. Latent growth curve modelling and time-lagged mixed-effects models will examine mediation.  Ethics and dissemination: Ethical approval was obtained from the University of Melbourne Human Research Ethics Committee (Project ID: 31186). This manuscript is based on protocol V.4.0 (06–04-26). Recruitment is ongoing. Results will be disseminated via peer-reviewed publications and presentations at scientific meetings.  Trial registration number: NCT06940596.
SN  - 2044-6055
SN  - 2044-6055
ER  -